TY  - JOUR
AU  - Guerrero, Whitney L.
AU  - Munene, Gitonga
AU  - Dickson, Paxton V.
AU  - Darby, Dina
AU  - Davidoff, Andrew M.
AU  - Martin, Michael G.
AU  - Glazer, Evan S.
AU  - Shibata, David
AU  - Deneve, Jeremiah L.
PY  - 2018
TI  - Early experience with cytoreduction and hyperthermic intraperitoneal chemotherapy at a newly developed center for peritoneal malignancy
JF  - Journal of Gastrointestinal Oncology; Vol 9, No 2 (April 16, 2018): Journal of Gastrointestinal Oncology
Y2  - 2018
KW  - 
N2  - Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has improved outcomes for patients with peritoneal carcinomatosis (PC). We present our experience from a newly developed peritoneal surface malignancy program.   Methods: An IRB approved retrospective review was performed for the first 50 patients treated with CRS/ HIPEC with clinicopathologic data described.   Results: Patients treated with CRS/HIPEC were Caucasian (64%), female (66%) with a median age of 53 years (range, 11–73 years). Primary pathology included: appendix (42%, n=21), ovary (18%, n=9), colon (14%, n=7), desmoplastic small round cell tumor (14%, n=7) or other (12%, n=6). The median peritoneal cancer index (PCI) score was 15.5 (range, 1–39) and 92% underwent complete cytoreduction (CCR 0/1). Median hospital length of stay was 9.0 days (range, 6–35 days). Eight patients (16%) suffered major morbidity with 2 (4%) 30-day mortalities.   Conclusions: Short-term outcomes observed after CRS/HIPEC in a newly developed center for PC are consistent with published higher volume center experiences.
UR  - https://jgo.amegroups.org/article/view/18443